Biogen's highly anticipated anti-LINGO data fall flat
This article was originally published in Scrip
After several months of questions about when Biogen Idec would reveal its first proof-of-concept data for the anti-LINGO development program, the company reported results from a Phase II clinical trial in the treatment of acute optic neuritis (AON) that gave no clear answers about the treatment's effects in multiple sclerosis (MS).
You may also be interested in...
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
Amunix’s XTEN technology for half-life extension and precise drug delivery has been used by multiple partners over the past 15 years, but now the firm is building its own cancer therapy pipeline.
Private Company Edition: Clover’s $230m financing was the largest of recent mega-rounds. Century Therapeutics ($160m), Vividion ($135m) and eGenesis ($125m) also raised big rounds and investors Foresite Capital ($969m), Sofinnova Partners ($540m) and OMX Ventures ($150m) raised new VC funds.